Results 151 to 160 of about 85,640 (310)
Effect of Belimumab on the Cutaneous Manifestations of Patients With Lupus Erythematosus
International Journal of Dermatology, EarlyView.ABSTRACT Background The aim was to assess the long‐term effect of belimumab on the cutaneous manifestations of patients with systemic lupus erythematosus (SLE). Methods The retrospective analysis included 29 patients with SLE. Cutaneous disease activity was assessed using the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) and the
Diana Schellin +5 more
wiley +1 more source
International Journal of Dermatology, EarlyView.ABSTRACT Background Atopic dermatitis (AD) is a chronic inflammatory skin disease with significant physical and psychosocial burden. Dupilumab, a monoclonal antibody targeting IL‐4Rα, has proven to be effective for moderate‐to‐severe AD, but long‐term real‐world data remain limited.
Francesco Leo +11 more
wiley +1 more source
Ankle Magnetic Resonance Imaging in Juvenile Idiopathic Arthritis Versus Non-Juvenile Idiopathic Arthritis Patients with Arthralgia [PDF]
, 2022 Monika Ostrowska +5 more
openalex +1 more source
Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open‐label extension study
Journal of the European Academy of Dermatology and Venereology, EarlyView.This study evaluated long‐term safety and efficacy in patients with moderate‐to‐severe atopic dermatitis. Patients with and without previous nemolizumab experience received nemolizumab 30 mg Q4W plus TCS/TCI. Nemolizumab was well‐tolerated through 104 weeks with clinically meaningful improvements in disease signs and symptoms.
Matthias Augustin +24 more
wiley +1 more source
Efficacy and safety of brodalumab in palmoplantar pustulosis: A 68‐week randomized Phase 3 trial
Journal of the European Academy of Dermatology and Venereology, EarlyView.This open‐label study is a continuation of the 16‐week double‐blind, Phase 3 trial assessing the efficacy and safety of brodalumab 210 mg subcutaneously, till a 68‐week extension period. Continued improvement was seen in the PPPASI 50/75/90 responses, PPPSI scores, PGA 0/1 responses and DLQI. Abstract Background The efficacy and safety of brodalumab in
Masamoto Murakami +6 more
wiley +1 more source
For optimal treatment of musculoskeletal pain among elderly individuals, clarification of its aetiology is essential [PDF]
Malaysian Family PhysicianJosef Finsterer
doaj +1 more source
Knee Arthralgia and Cartilage Thinning in Psoriasis: Clues to Early Psoriatic Arthritis? [PDF]
Semra Aktürk +8 more
openalex +1 more source
52-Year-Old Man With Arthralgias, Fever, and Fatigue [PDF]
, 2010 Niti R. Aggarwal, Jason H. Szostek
openalex +1 more source